3,744-subject cohort
Prevalent lung cancer types/subtypes and non-cancer controls.

LiquidLung
LiquidLung is developing LiquidLung-EDT™ — an RNA-powered blood test designed to help identify lung cancer earlier in high-risk individuals, before symptoms appear, when treatment options may be more effective.
Earlier signal. Clearer triage. Better screening participation.
02The Problem
Lung cancer remains the leading cause of cancer death in the United States. The tragedy is not only that lung cancer is deadly, it is that too many cases are discovered after the window for earlier intervention has already narrowed.
When lung cancer is found while still localized, 5-year relative survival is dramatically higher than when it is found after distant spread. But today, the majority of lung cancers are diagnosed at advanced stages.


03Why Current Screening Falls Short
Annual low-dose CT screening is recommended for high-risk adults. But real-world participation remains limited by awareness, access, scheduling friction, patient anxiety, workflow burden, and other practical barriers.
For many patients, getting to an imaging appointment is not simple. It can mean time away from work, transportation challenges, anxiety about the scan, and uncertainty about whether they truly need it.
LiquidLung-EDT™ is being developed to meet patients earlier in the pathway, through a blood draw that can help identify who may need imaging next.

04The Solution
Meet LiquidLung-EDT™ — an RNA-based blood test in development to help guide high-risk individuals toward appropriate lung cancer screening.
01
Eligible by age, smoking history, or other risk factors.
02
Simple blood draw during routine care or screening outreach.
03
RNA-based signature evaluates lung cancer-associated biology.
04
Positive results may support imaging escalation.
Illustrative proposed workflow. LiquidLung remains investigational and is not available for clinical use.
05Positioning Statement
LDCT remains an important tool in lung cancer screening.
LiquidLung-EDT™ is being developed as a targeted molecular triage tool, a simple blood test designed to help bring the right patients into imaging at the right time.

06The Science
Many blood-based cancer detection approaches focus on tumor-derived DNA. But early tumors may shed very little DNA, making the earliest-stage disease difficult to detect.
LiquidLung-EDT™ focuses on cell-free RNA, which can reflect active biological processes in real time.
Our patented dual-source cfRNA approach is designed to capture two complementary sources of signal:

Blood sample
Dual-source cfRNA
When integrated, these dual sources of active RNA expression yield a stronger signal in early-stage disease than tumor material alone.
07Why LiquidLung Is Different
LiquidLung-EDT™ is designed around the idea that early lung cancer may create detectable biological changes before tumor burden is large enough to reliably capture through tumor-derived DNA.
By measuring RNA signals associated with both the body’s response and lung/tumor context, LiquidLung-EDT™is being developed to detect early-stage disease biology in blood.
Dual-source cfRNA captures active disease biology.
A blood-first approach designed to support LDCT triage.
Designed for clinical laboratory workflows and broad screening use.
08Evidence & Readiness
Our technology has been validated in more than 5,000 patients.
LiquidLung’s published ASCO work evaluated a machine-learning approach using RNA gene expression in a large, predominantly early-stage lung cancer cohort.
In a 3,744-subject cohort, the LiquidLung-EDT™ signature achieved 98% sensitivity and 89% specificity in a held-out test set.
The cohort was heavily weighted toward early-stage lung cancer, with broad representation across histologic types.
Prevalent lung cancer types/subtypes and non-cancer controls.
Performance in the held-out test set.
The lung cancer cohort was heavily weighted toward Stage I/II disease.
These figures are results from the described research cohort. They are not established real-world screening performance. LiquidLung remains investigational, is not FDA-approved or commercially available, and has not been clinically validated for screening.
09Our Origins
Built for lung health.
LiquidLung is a focused lung health franchise created within IVBH, a creative-technical studio built to discover hidden biological meaning and translate it into real-world products.
IVBH starts with a belief that disease rarely reveals itself through a single obvious signal. Long before disease becomes clinically apparent, subtle changes are already occurring across biology. By searching the relationships among those signals, IVBH works to discover biological signatures that can become the source material for earlier detection.
LiquidLung was purpose-built to carry that work forward in lung health. Our first frontier is lung cancer, one of the clearest examples of a disease where knowing sooner can change everything.

10Partner With LiquidLung
LiquidLung is seeking clinical, laboratory, diagnostic, imaging, strategic, and commercial partners interested in advancing blood-based lung cancer screening and triage.